Abbott Laboratories
ABT
$100.30
-2.36%
Abbott Laboratories is a global healthcare leader that manufactures and markets a diversified portfolio of products, including cardiovascular and diabetes devices, diagnostic equipment, nutritional products, and branded generic drugs. The company is a dominant player across its key segments, particularly in medical devices with its continuous glucose monitoring systems and structural heart technologies, and it derives significant international revenue, which provides geographic diversification. The current investor narrative is focused on the stock's significant price decline, which some view as a long-term buying opportunity, while also weighing the company's resilient underlying growth in medical devices, its strategic acquisition of Exact Sciences, and its impressive 54-year track record of consecutive dividend increases.…
ABT
Abbott Laboratories
$100.30
Related headlines
Investment Opinion: Should I buy ABT Today?
Rating & Thesis: Hold. Abbott Laboratories is a high-quality company caught in a significant downtrend; investors should wait for evidence of a fundamental or technical bottom before initiating new positions, despite its attractive long-term attributes. This aligns with the limited analyst data but acknowledges the positive institutional sentiment as a counterpoint.
Supporting Evidence: The recommendation is supported by four key data points. First, the forward P/E of 16.4x is reasonable but not a screaming bargain without accelerating growth. Second, revenue growth has decelerated to 4.4% YoY. Third, while profitability is strong (57.1% gross margin), operating margin of 19.6% shows some pressure. Fourth, the stock trades just 1% above its 52-week low, indicating severe technical damage that may not be fully resolved.
Risks & Conditions: The two biggest risks are continued earnings disappointment leading to further multiple compression and a failure of the stock to find technical support, breaking below $99.34. This Hold would upgrade to a Buy if the stock demonstrates a confirmed reversal pattern above $110, or if forward earnings estimates are revised upward meaningfully. It would downgrade to a Sell on a sustained break below $99 with high volume. Relative to its history and the current growth trajectory, the stock appears fairly valued to slightly undervalued on a forward basis, but the technical overhang is significant.
Sign up to view all
ABT 12-Month Price Forecast
The outlook is balanced with a slight skew to caution. The base case (50% probability) of stabilization and modest recovery is most likely, given the reasonable forward valuation and strong cash flow, which should put a floor under the stock. However, the severe technical damage and growth deceleration warrant a neutral stance until a clearer bottom is established. The stance would upgrade to bullish on a sustained breakout above $115 on strong volume, confirming a trend reversal. It would downgrade to bearish on a confirmed weekly close below $99, signaling a breakdown from the current consolidation.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Abbott Laboratories's 12-month outlook, with a consensus price target around $130.39 and implied upside of +30.0% versus the current price.
Average Target
$130.39
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$80 - $130
Analyst target range
Analyst coverage data is limited, with only two analysts providing estimates for revenue and EPS, which is insufficient to derive a robust consensus price target or recommendation distribution; this limited coverage is unusual for a large-cap company like Abbott and may indicate a period of transition or uncertainty following its recent earnings report and guidance. Without a clear average target price, the implied upside or downside cannot be calculated, and the wide range between the high and low EPS estimates ($8.43 vs. $8.30) suggests some variance in expectations, though the range is relatively tight; the recent institutional ratings from firms like Citigroup, Barclays, and RBC Capital are unanimously positive (Buy/Overweight/Outperform), indicating strong professional sentiment that the current price weakness is a buying opportunity.
Bulls vs Bears: ABT Investment Factors
The evidence presents a stark conflict between deteriorating price action and a fundamentally sound, cash-generative business. The bear side currently has stronger evidence in the near term, as the severe technical breakdown and persistent selling pressure are undeniable. However, the bull case is built on a foundation of financial strength, a reasonable forward valuation, and unanimous institutional support for the long term. The single most important tension in the investment debate is whether the current price decline is a rational repricing of decelerating growth or an irrational overreaction that has created a compelling value opportunity in a high-quality Dividend Aristocrat.
Bullish
- Strong Financial Health & Cash Flow: Abbott generates substantial free cash flow of $7.4 billion TTM, supporting its dividend and strategic moves. Its balance sheet is robust with a low debt-to-equity ratio of 0.29 and a healthy current ratio of 1.58, providing significant financial flexibility.
- Attractive Forward Valuation: The stock trades at a forward P/E of 16.4x, which is reasonable for a diversified healthcare leader and represents a significant discount to its trailing P/E of 33.6x. This forward multiple suggests the market has already priced in an earnings normalization.
- Dividend Aristocrat with 54-Year Streak: Abbott's 54-year history of consecutive dividend increases, including its recent 409th consecutive quarterly payment, signals exceptional financial stability and a commitment to shareholder returns, making it a core holding for income-focused portfolios.
- Resilient Underlying Business Growth: Despite the stock's decline, Q4 2025 revenue grew 4.4% YoY to $11.46 billion, and the company maintains strong profitability with a gross margin of 57.1%. This demonstrates the core business's resilience amid market pessimism.
Bearish
- Severe Technical Downtrend & Weakness: The stock is down 19.4% over the past year and 24.3% over six months, trading at just 72% of its 52-week high-to-low range. Persistent negative momentum, including a 9.0% drop in the past month, shows a clear lack of buying support.
- Elevated Trailing P/E & Earnings Compression: The trailing P/E of 33.6x is historically high for Abbott, reflecting earnings that have not yet adjusted downward to match the stock's price decline. This indicates the market may still be expecting a higher level of profitability than is currently being delivered.
- Revenue Growth Deceleration: While Q4 revenue grew 4.4% YoY, this represents a deceleration from higher growth rates in prior 2025 quarters. This normalization post-pandemic raises questions about the company's ability to re-accelerate top-line expansion in the near term.
- Limited Analyst Coverage & Uncertainty: Only two analysts are providing estimates for revenue and EPS, which is unusually low for a large-cap company and suggests a period of transition or uncertainty following recent results and guidance, making it harder to gauge consensus expectations.
ABT Technical Analysis
The stock is in a pronounced downtrend, having declined 19.44% over the past year and 24.34% over the last six months. With a current price of $100.30, it is trading near the bottom of its 52-week range, at just 72% of the distance from its 52-week low of $99.34 to its high of $139.06, indicating significant technical weakness and positioning it as a potential value opportunity, albeit one that has yet to find a durable bottom. Recent momentum remains decisively negative, with the stock down 9.02% over the past month and 20.35% over the past three months, which aligns with and accelerates the longer-term downtrend; this persistent selling pressure suggests a lack of near-term catalysts to arrest the decline. Key technical support is clearly defined at the 52-week low of $99.34, with a breakdown below this level potentially signaling further downside, while resistance lies near the 52-week high of $139.06; the stock's beta of 0.782 indicates it has been less volatile than the broader market during this sell-off, which may offer some relative stability but does not negate the bearish price action.
Beta
0.78
0.78x market volatility
Max Drawdown
-27.4%
Largest decline past year
52-Week Range
$99-$139
Price range past year
Annual Return
-19.4%
Cumulative gain past year
| Period | ABT Return | S&P 500 |
|---|---|---|
| 1m | -9.0% | +2.6% |
| 3m | -20.3% | -2.3% |
| 6m | -24.3% | +2.6% |
| 1y | -19.4% | +27.3% |
| ytd | -19.2% | -0.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABT Fundamental Analysis
Revenue growth remains positive but modest, with Q4 2025 revenue of $11.46 billion representing a 4.4% year-over-year increase; however, this growth rate has decelerated from the higher levels seen in prior quarters of 2025, indicating a normalization post-pandemic. The company is highly profitable, with Q4 2025 net income of $1.78 billion and a robust gross margin of 57.05%, though the operating margin of 19.6% shows some pressure relative to the gross margin, reflecting ongoing investments in R&D and SG&A. Financially, Abbott is in a strong position with a healthy current ratio of 1.58, a conservative debt-to-equity ratio of 0.29, and substantial free cash flow generation of $7.40 billion on a trailing-twelve-month basis, which comfortably funds its dividend and share repurchases while supporting strategic acquisitions.
Quarterly Revenue
$11.5B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.57%
Latest Quarter
Free Cash Flow
$7.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABT Overvalued?
Given its positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 33.55x, which is significantly higher than its forward PE of 16.42x; this wide gap reflects market expectations for a substantial recovery in earnings over the next twelve months. Compared to typical medical device peers, Abbott's forward PE of 16.4x appears reasonable, though a direct industry average is not provided in the data; the valuation premium is likely supported by its diversified business model, strong cash flow, and dividend aristocrat status. Historically, the current trailing PE of 33.55x is elevated compared to its own range over the past several years, which has often fluctuated between the high-teens and low-30s, suggesting the market is still pricing in a high level of earnings from the prior year's base, but the forward multiple indicates expectations are for normalization.
PE
33.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 5x~46x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Abbott's primary financial risk is earnings compression, as evidenced by the wide gap between its elevated trailing P/E of 33.6x and its forward P/E of 16.4x. The market is pricing in a significant earnings recovery; failure to meet these expectations could lead to further multiple contraction. While the balance sheet is strong, the deceleration in revenue growth to 4.4% YoY in Q4 raises operational risk, particularly if this trend continues across its key device and diagnostic segments. The company's international revenue exposure (~60% of sales) also introduces currency and geopolitical volatility.
Market & Competitive Risks: The stock faces substantial valuation compression risk. Trading near a 52-week low after a 19.4% annual decline, it has already undergone significant de-rating, but its forward P/E of 16.4x, while reasonable, is not deeply discounted if growth continues to slow. Competitive risks are inherent in medical devices, especially in continuous glucose monitoring and structural heart markets. Furthermore, the stock's low beta of 0.78 has not protected it from severe underperformance, indicating company-specific issues are driving the sell-off more than broader market conditions.
Worst-Case Scenario: The worst-case scenario involves a breakdown below the key technical support at the 52-week low of $99.34, triggering a new wave of selling. This could be catalyzed by a guidance cut, a major product setback, or a broader sector rotation out of healthcare. In this adverse scenario, the stock could realistically test levels implied by its maximum drawdown of -27.4%, which from the current price of $100.30 would target approximately $72.80. A more immediate, measured downside would be a retest and breach of the $99.34 low, representing a potential loss of -1% from current levels, with further downside to the mid-$90s if sentiment fails to improve.
FAQ
The key risks are, in order of severity: 1) Technical & Sentiment Risk: The stock is in a severe downtrend, down 24% over six months, and breaking below $99.34 support could trigger further selling. 2) Execution & Growth Risk: Revenue growth decelerated to 4.4% YoY; failure to re-accelerate could compress the valuation multiple further. 3) Earnings Compression Risk: The wide gap between trailing (33.6x) and forward (16.4x) P/E requires perfect execution; any earnings miss would be punished. 4) Competitive Risk: Intense competition in medical devices, especially diabetes care, could pressure margins and market share.
The 12-month forecast outlines three scenarios. The Base Case (50% probability) targets $110-$125, assuming stabilization and meeting current EPS estimates. The Bull Case (30% probability) targets $130-$139, driven by re-accelerating growth and restored investor confidence. The Bear Case (20% probability) targets $95-$105, triggered by earnings misses and a breakdown below key support. The Base Case is most likely, predicated on the company's strong fundamentals eventually outweighing the current negative sentiment, leading to a gradual recovery as earnings normalize.
ABT's valuation sends mixed signals. Its trailing P/E of 33.6x is elevated and suggests overvaluation based on past earnings. However, its forward P/E of 16.4x is reasonable for a diversified healthcare leader and implies the market expects significant earnings growth. Compared to its own 52-week high, the stock is deeply undervalued. On a forward-looking basis, it appears fairly valued to slightly undervalued, but this hinges entirely on the company meeting its forward EPS estimates of ~$8.39. The market is currently pricing in a successful earnings recovery.
ABT presents a complex risk/reward profile. For long-term dividend growth investors, the current price near a 52-week low and a forward P/E of 16.4x may represent a good entry point for a high-quality company. The 54-year dividend growth streak and strong free cash flow are powerful attractions. However, for shorter-term investors, the severe downtrend and decelerating revenue growth (4.4% in Q4) pose significant near-term risks. It is a good buy for patient, income-focused investors willing to average in, but traders should wait for a confirmed technical reversal.
ABT is unequivocally suited for long-term investment. Its Dividend Aristocrat status, global diversified business, and strong cash flow generation are hallmarks of a core long-term holding. The current volatility and downtrend make it a poor candidate for short-term trading. Given the need for the growth narrative to rebuild and the technical base to form, investors should have a minimum horizon of 2-3 years to allow the company's fundamental strengths and dividend compounding to work. Its low beta of 0.78 also supports its role as a stabilizing, long-term portfolio holding rather than a short-term trade.